ArticleFrontiers in pharmacology2026
Hepatoprotective action of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) threatens public health worldwide, and Methods: In this study, Results: DOP markedly alleviated hepatic lipid accumulation, restored liver function abnormalities and mitigated hepatic pathological damage. DOP reshaped the disturbed gut flora: it reduced lipopolysaccharide (LPS)-enriched Gram-negative bacteria, elevated short-chain fatty acid-producing probiotics, modified intestinal metabolites, repaired the intestinal barrier and prevented intestinal LPS leakage. Both cellular and animal experiments demonstrated that DOP down-regulated TLR4, MyD88 and NF-κB p65 levels, increased IκBα expression and suppressed downstream pro-inflammatory mediators. Discussion: Collectively, DOP confers protective effects against MAFLD through remodeling gut microbiota and intestinal metabolites, preserving intestinal-barrier integrity, and inhibiting LPS-provoked hepatic TLR4/NF-κB inflammatory activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.